Outcome of tocilizumab treatment in refractory ocular inflammatory diseases

Acta Ophthalmologica

Volumn 94, Issue 6, 2016, Pages e400-e406

  Silpa archa, Sukhum ^a,b,c   Oray, Merih ^a,b,d   Preble, Janine M ^a,b   Foster, Charles Stephen ^a,b,e  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b Ocular Immunology and Uveitis Foundation   (United States)

^c RANGSIT UNIVERSITY   (Thailand)

^d ISTANBUL UNIVERSITY   (Turkey)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

inflammation; scleritis; tocilizumab; uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALPHA2A INTERFERON; AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; TOCILIZUMAB;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BLISTER; CASE STUDY; CHEST TIGHTNESS; CHORIORETINOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EYE INFLAMMATION; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; LOADING DRUG DOSE; MALE; NAUSEA; NEUTROPENIA; ORBIT PSEUDOTUMOR; POSTERIOR SCLERITIS; PRIORITY JOURNAL; RETINA VASCULITIS; RETROSPECTIVE STUDY; SCLERITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 84984619845     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.13015     Document Type: Article

References (23)

1. Adan A, Mesquida M, Llorenç V, Espinosa G, Molins B, Hernández MV & Pelegrín L (2013): Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 251: 2627–2632.
2. de Boer JH, van Haren MA, de Vries-Knoppert WA, Baarsma GS, de Jong PV, Postema FJ, Rademakers AJ & Kijlstra A (1992): Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Curr Eye Res 11(Suppl): 181–186.
3. De Benedetti F, Brunner HI, Ruperto N et al. (2012): Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367: 2385–2395.
4. Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS & Foster CS (2011): Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol 56: 474–510.
5. Franks WA, Limb GA, Stanford MR, Ogilvie J, Wolstencroft RA, Chignell AH & Dumonde DC (1992): Cytokines in human intraocular inflammation. Curr Eye Res 11(Suppl): 187–191.
6. Gomes Bittencourt M, Sepah YJ, Do DV et al. (2012): New treatment options for noninfectious uveitis. Dev Ophthalmol 51: 134–161.
7. Jabs DA, Nussenblatt RB & Rosenbaum JT (2005): Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140: 509–516.
8. Koike T, Harigai M, Inokuma S et al. (2014): Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41: 15–23.
9. Mesquida M, Molins B, Llorenc V, Llorenç V, Sainz de la Maza M & Adán A (2014): Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology 121: 2380–2386.
10. Nussenblatt RB, Palestine AG, Chan CC & Roberge F (1985): Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92: 467–471.
11. Ohta K, Yamagami S, Taylor AW & Streilein JW (2000a): IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 41: 2591–2599.
12. Ohta K, Wiggert B, Yamagami S, Taylor AW & Streilein JW (2000b): Analysis of immunomodulatory activities of aqueous humor from eyes of mice with experimental autoimmune uveitis. J Immunol 164: 1185–1192.
13. Papo M, Bielefeld P, Vallet H et al. (2014): Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol 32: S75–79.
14. Perez VL, Papaliodis GN, Chu D, Anzaar F, Christen W & Foster CS (2004): Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm 12: 193–201.
15. Romano M, Sironi M, Toniatti C et al. (1997): Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6: 315–325.
16. Rothova A, Suttorp-van Schulten MS, Frits Treffers W & Kijlstra A (1996): Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80: 332–336.
17. de Smet MD, Taylor SR, Bodaghi B et al. (2011): Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 30: 452–470.
18. Smolen JS, Beaulieu A, Rubbert-Roth A et al. (2008): Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987–997.
19. Suelves AM, Arcinue CA, González-Martín JM, Kruh JN & Foster CS (2013): Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease. Ophthalmology 120: 1201–1209.
20. Tappeiner C, Heinz C, Ganser G & Heiligenhaus A (2012): Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39: 1294–1295.
21. Tode J, Zeuner R, Saeger M, Roider J & Nölle B (2015): Tocilizumab and steroid boli for treatment-resistant anterior necrotizing scleritis. Acta Ophthalmol 93: e683–e684.
22. Venkiteshwaran A (2009): Tocilizumab. MAbs 1: 432–438.
23. Yokota S, Imagawa T, Mori M et al. (2014): Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 41: 759–767.